US-based Alexion Pharmaceuticals' supplemental biologics licence application (sBLA) for priority review of Ultomiris has been approved by the US Food and Drug Administration (FDA), it was reported on Friday.
The product is intended to treat people with aHUS, a disease of the red blood cells, and inhibition of complement-mediated thrombotic microangiopathy. It is said to be the first and only long-acting C5 inhibitor administered every eight weeks and it works by inhibiting the C5 protein in the terminal complement cascade.
Alexion Pharmaceuticals has submitted the sBLA based on results of the phase three study of Ultomiris that achieved its primary objective in complement inhibitor-naive patients with Atypical HUS. The global, multicentre, single arm and phase three study evaluated the safety and efficacy of Ultomiris administered by intravenous infusion in 56 adults who had not been treated with a complement inhibitor before. The trial included up to seven-day screening period, a 26-week initial evaluation period and an extension period of up to two years, which is still ongoing.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML